A new study shows that tumor cells depleted of ARID1A — a protein that acts as a cancer suppressor — become highly sensitive to anticancer poly ADP ribose polymerase (PARP) inhibitor drugs after radiation treatment. The research could advance efforts to treat many human cancers with loss of ARID1A that are resistant to current standard treatments, the study team suggests.